FDA
approval
· 2018-06-22
FDA Approved: APTIVUS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
Summary
FDA approved a supplemental application for APTIVUS (tipranavir) by Boehringer Ingelheim Pharmaceuticals, expanding its labeling.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for APTIVUS (TIPRANAVIR)